Ana Cristina Silva-Pinto, Fernando F Costa, Sandra Fatima Menosi Gualandro, Patricia Belintani Blum Fonseca, Carmela Maggiuzzu Grindler, Homero C R Souza Filho, Carolina Tosin Bueno, Rodolfo D Cançado
Background: Sickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of the population has the sickle cell trait in Brazil, and 60,000 to 100,000 have SCD. However, despite recognizing the significant burden of disease, little is known about SCD costs.
Objective: To estimate SCD societal costs based on disease burden modelling, under Brazilian societal perspective.
Methods: A disease burden model was built considering the societal perspective and a one-year time horizon, including direct medical and indirect costs (morbidity and mortality). The sum of life lost and disability years was considered to estimate disability-adjusted life years (DALYs). Data from a public database (DATASUS) and the prevalence obtained from literature or medical experts were used to define complications prevalence and duration. Costs were defined using data from the Brazilian public healthcare system table of procedures and medications (SIGTAP) and the human capital method.
Results: Annual SCD cost was 413,639,180 USD. Indirect cost accounted for the majority of burden (70.1% of the total; 290,158,365 USD vs 123,480,816 USD). Standard of care and chronic complications were the main source of direct costs among adults, while acute conditions were the main source among children. Vaso-occlusive crisis represented the complication with the highest total cost per year in both populations, 11,400,410 USD among adults and 11,510,960 USD among children.
Conclusions: SCD management may impose an important economic burden on Brazilian society that may reach more than 400 million USD per year.
